Orvepitant - NeRRe therapeutics

Drug Profile

Orvepitant - NeRRe therapeutics

Alternative Names: 823296; GW 823296; GW823296X

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer NeRRe Therapeutics
  • Class Amides; Antidepressants; Antipruritics; Antitussives; Anxiolytics; Piperidines; Pyrazines; Pyrroles
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cough; Pruritus
  • Discontinued Anxiety disorders; Major depressive disorder; Post-traumatic stress disorders

Most Recent Events

  • 24 May 2018 Nerre Therapeutics plans a phase I study to assess the effect of itraconazole on the pharmacokinetics of orvepitant in healthy volunteers (NCT03535662)
  • 09 May 2018 Nerre Therapeutics withdraws the phase II SOOTHE trial for Pruritus associated with atopic dermatitis prior to enrolment due to strategic decision (PO) (NCT03464526)
  • 14 Mar 2018 Nerre Therapeutics plans the SOOTHE phase II trial for Pruritus associated with atopic dermatitis in May 2018 (PO) , (NCT03464526)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top